Non-Communicable Disease and Healthcare System Developments
Reversal of a Landmark Retinal Trial: Stereotactic Radiotherapy for Neovascular AMD
The STAR trial’s extended year 3–4 follow-up (BMJ), published this period, substantially revises the clinical picture established by the trial’s original two-year primary outcome. Among 411 participants with chronic, pretreated neovascular age-related macular degeneration randomised to one-off 16 Gy stereotactic radiotherapy (SRT) versus sham SRT, the SRT group continued to require fewer anti-VEGF injections through year 4 (mean 19.1 versus 21.6 over four years; adjusted decrease of 3.2 injections), reproducing the treatment-burden benefit that drove initial interest in the technology. However, final visual acuity in the SRT group was 8.3 letters worse than in the sham group—a clinically meaningful deficit that effectively reverses the favourable interpretation of the year-2 data. Reading-centre-detected microvascular abnormalities were markedly more frequent in SRT-treated eyes (58% versus 16% in sham-treated eyes), pointing to a radiation-associated microvascular injury mechanism that becomes clinically apparent only with longer follow-up. The authors’ own conclusion—that the findings “no longer support the use of SRT to treat neovascular AMD”—is a notable case study in the risk of premature adoption based on short-term composite outcomes, and is directly relevant to any jurisdiction where SRT devices for AMD have entered or are being considered for routine ophthalmic practice.
Oral FGFR Inhibition in Paediatric Achondroplasia
A phase 3, multicentre, double-blind, placebo-controlled trial (NEJM) of oral infigratinib—an FGFR1–3 tyrosine kinase inhibitor—in 114 children with achondroplasia (ages 3–17) found a significant treatment effect on annualised height velocity at week 52 (least-squares mean difference 1.74 cm/year versus placebo; 95% CI 1.31–2.17; P<0.001), alongside significant improvement in height z-score. Adverse event rates were similarly high in both arms (96% infigratinib versus 95% placebo), and no serious adverse events or discontinuations were attributed to study treatment. This adds an oral, small-molecule alternative to the injectable growth-plate-targeted therapies (e.g., vosoritide) already in clinical use for achondroplasia, a genetic skeletal dysplasia caused by activating FGFR3 variants; longer-term data on final adult height and skeletal complications will be needed to establish its comparative role.
Lung Transplantation for Refractory Stage IV Non-Small Cell Lung Cancer
A prospective single-centre registry study (JAMA) examined outcomes of lung transplantation in patients with medically refractory, lung-limited stage IV non-small cell lung cancer (NSCLC) complicated by respiratory failure—a population historically excluded from transplantation due to oncological concerns. Among 98 eligible patients, 17 underwent transplantation and 81 received medical management alone for nonbiologic reasons. One-year overall survival was 100% in the transplant group versus 40.8% in the medically managed group (absolute difference 59.2 percentage points), and 1-year post-transplant survival among NSCLC recipients was comparable to that of 306 concurrent non-cancer lung transplant recipients (100% versus 88.1%). While the small, non-randomised, single-centre design and selection for exceptionally favourable candidates limit generalisability, the magnitude of the survival difference is striking and may prompt reconsideration of transplant eligibility criteria for a narrowly defined subset of stage IV NSCLC patients with organ-limited, non-metastatic-elsewhere disease.
Infectious Diseases: Global Perspective
Respiratory and Droplet Transmission
Ebola Disease Outbreak (Bundibugyo Virus) — Democratic Republic of the Congo, Uganda, and France
The Bundibugyo virus disease (BVD) outbreak in the Democratic Republic of the Congo continued its rapid escalation this reporting period. As of 1 July 2026, DRC had recorded 1,460 confirmed cases and 452 deaths (crude case fatality ratio 30.9%), representing an increase of 564 confirmed cases and 220 deaths since the previous WHO Disease Outbreak News of 19 June—growth partly attributable to scaled-up surveillance and testing capacity rather than transmission acceleration alone, though the absolute increase remains substantial by any measure. Ituri Province remains overwhelmingly dominant, accounting for 91.3% of cases (1,333/1,460) and 84% of deaths (380/452), with the highest health-zone burdens in Bunia (416 cases), Rwampara (308), and Mongbwalu (270). Of particular epidemiological significance, three confirmed cases with travel history from Nia Nia health zone (Ituri) were identified on 30 June in Wamba health zone (Haut-Uele Province) and in Kisangani (Tshopo Province)—the first documented spread beyond the three previously affected provinces (Ituri, North Kivu, South Kivu), extending the outbreak’s geographic footprint via population mobility rather than contiguous transmission. Health and care worker infections now total 102 confirmed cases (25 deaths), underscoring persistent nosocomial transmission risk. Contact tracing covers 10,821 identified contacts across Ituri and North Kivu, with follow-up completion rates of 83.2% and 81% respectively—rates that, while improved, still leave meaningful proportions of contacts unmonitored in a security-constrained, conflict-affected operating environment characterised by population displacement and disrupted access for response teams.
In Uganda, the outbreak has shown sustained containment: no new confirmed cases have been reported since 21 June, holding the cumulative total at 20 confirmed cases (two deaths) plus one fatal probable case, with 821 of 831 all-time contacts having completed 21-day follow-up. All Ugandan transmission remains linked to importation from DRC and limited to the Kampala Metropolitan Area (Kampala and Wakiso districts), with no documented community transmission.
The most consequential development for the EU/EEA this period is the confirmation, on 24 June, of the outbreak’s first case within the European Union: a middle-aged male humanitarian doctor who had spent five weeks in Ituri Province caring for BVD patients. He self-reported symptoms on arrival at Charles de Gaulle Airport on 23 June, prompting immediate isolation and PCR-confirmed diagnosis; at the time of reporting he remained clinically stable, afebrile, and without haemorrhagic or gastrointestinal manifestations. French authorities identified and isolated the patient’s contacts, and a parallel contact-tracing effort has listed 107 contacts in Kinshasa. This importation—the first BVD case detected on European soil—represents exactly the scenario ECDC has been monitoring epidemic intelligence for since the outbreak’s May declaration, and its successful early detection via traveller self-reporting (rather than airport screening) reinforces ECDC’s standing assessment that exit screening and traveller symptom awareness, not incoming-traveller screening, are the more effective control lever.
Bundibugyo virus disease is caused by an Orthoebolavirus species distinct from the more familiar Zaire ebolavirus; the natural reservoir is believed to be fruit bats, with transmission to humans via contact with infected wildlife and subsequent human-to-human spread through blood, secretions, or contaminated surfaces, amplified in healthcare settings with inadequate infection prevention and control and during unsafe burial practices. The incubation period ranges from 2–21 days, with non-specific early symptoms (fever, fatigue, myalgia, headache, sore throat) progressing to gastrointestinal symptoms, organ dysfunction, and occasionally haemorrhagic manifestations; historical case fatality ratios for BVD outbreaks (2007 Uganda, 2012 DRC) were 30% and 50% respectively, consistent with the CFR now being observed in DRC. Critically, no licensed vaccine or specific treatment exists for Bundibugyo virus, unlike Zaire ebolavirus, for which ring vaccination and monoclonal antibody therapeutics are established response tools—a gap that continues to shape both the clinical management options available and the urgency behind EMA’s now-formalised engagement with the African Medicines Agency on candidate countermeasures (reported in this series previously). ECDC’s risk assessment, reiterated this week, holds that the likelihood of infection remains low for EU/EEA residents travelling to or living in affected areas, and very low for the general EU/EEA population, given the very low likelihood of onward transmission following importation; this assessment will be reviewed as further information, including the outcome of the French contact-tracing effort, becomes available.
Vector-Borne and Zoonotic Transmission
Global Animal Disease Notifications: Notable WOAH/WAHIS Signals
WOAH’s follow-up and immediate notification stream for the reporting period contains two developments of particular epidemiological interest beyond the routine background of recurrent avian influenza and African swine fever reporting typical of this system. First, Mexico reported two separate first-occurrence detections of Cochliomyia hominivorax (New World screwworm) in a zone or compartment, dated 4 June and 20 September 2025 (the latter a delayed report), continuing the northward re-expansion of this myiasis-causing parasite that has been under close surveillance across Central America and Mexico in recent years; screwworm infestation carries substantial veterinary and, less commonly, human health significance and has prompted heightened US-Mexico border livestock movement controls independent of this report. Second, the United Kingdom’s Heard and McDonald Islands—a remote, largely uninhabited sub-Antarctic territory—reported its first-ever occurrence of highly pathogenic avian influenza H5N1 in non-poultry wild birds (onset dated 3 January 2026), illustrating the continued southward geographic reach of clade 2.3.4.4b H5N1 into some of the most isolated wild bird colonies on Earth, with implications for Antarctic and sub-Antarctic seabird and marine mammal populations that have already experienced substantial H5N1-associated mortality events in recent years.
Beyond these two signals, the reporting period’s WOAH data also document ongoing recurrent detections of highly pathogenic avian influenza and African swine fever across a wide range of non-EU/EEA jurisdictions (Korea, South Africa, Chile, Kazakhstan, Bhutan, Nepal) alongside recurrent foot-and-mouth disease in Eswatini, Botswana, Vietnam, Eritrea, and Israel (the latter involving a new strain, SAT 1, not previously recorded in the country)—a background level of endemic transmisison consistent with expected patterns and not indicative of a new regional escalation.
Infectious Diseases: European Union/European Economic Area
Vector-Borne Transmission
Seasonal Surveillance: West Nile Virus and Crimean-Congo Haemorrhagic Fever
ECDC’s weekly seasonal surveillance reports both vector-borne threats tracking at expected early-season levels. As of 1 July, three countries—Italy, Romania, and North Macedonia—have reported a cumulative six human cases of West Nile virus infection across the EU/EEA in 2026 to date, with ECDC assessing current weather conditions as increasingly favourable for mosquito-borne transmission and anticipating rising case counts through the coming weeks; this is consistent with the pattern documented in this report series through recent weeks and does not yet represent a deviation from seasonal expectations. For Crimean-Congo haemorrhagic fever (CCHF), Spain has reported the only locally acquired case in Europe so far in 2026, in Salamanca—a finding ECDC characterises as unsurprising given the established regional presence of the Hyalomma tick vectors and prior local circulation of CCHF virus, with timing consistent with the expected seasonal peak in tick activity. Both events warrant continued routine monitoring rather than escalated concern at this stage, though CCHF surveillance carries particular relevance for Bulgaria given the country’s own endemic CCHF activity in prior seasons (national data below).
Seasonal Monitoring of Vibrio spp. Environmental Suitability
ECDC’s bathing-season Vibrio Viewer forecast identifies 13 Bulgarian municipalities across the Varna, Dobrich, and Burgas administrative areas as being at high environmental suitability risk for Vibrio spp. proliferation in coastal waters over the five-day period to 8 July, alongside comparable high-risk designations in France, Germany, Poland, Romania, Sweden, Estonia, and Lithuania. Vibrio infections, acquired through consumption of raw or undercooked shellfish or through wound exposure to contaminated brackish or coastal water, range clinically from self-limiting gastroenteritis to severe wound infections and, in individuals with diabetes, chronic liver disease, or immunosuppression, invasive septicaemic disease. ECDC attributes the expanding geographic suitability for Vibrio growth to climate-driven warming of coastal waters, and recommends standard precautions—thorough seafood cooking and avoidance of open-wound exposure to brackish or coastal water—for residents and visitors in the flagged areas, which include Bulgaria’s principal Black Sea coastal municipalities during the peak of the summer bathing season.
Fecal-Oral Transmission
Multi-Country Salmonella Stanley Outbreak Linked to Flavoured Noodle Products
ECDC and the European Food Safety Authority published a joint Rapid Outbreak Assessment on 1 July 2026 addressing a multi-country outbreak of Salmonella Stanley sequence type ST2045 infections linked to consumption of flavoured instant noodle products. This is a newly flagged food-safety signal for this report series; further country-level case distribution and the specific implicated product(s) were not detailed in the source material available this period, and follow-up reporting is warranted as the assessment’s findings are disseminated.
Contact and Sexual Transmission
Emerging Risk Assessment: Ceftriaxone-Resistant Gonorrhoea
An ECDC Internal Response Team has been convened to produce a formal Risk Assessment—expected by 17 July 2026—on the increasing number of ceftriaxone-resistant Neisseria gonorrhoeae infections and evidence of local (as opposed to purely travel-associated) transmission within the EU/EEA. Ceftriaxone is the last remaining first-line empirical therapy for gonorrhoea in most European treatment guidelines, and documented local transmission of resistant strains—rather than isolated imported cases—would represent a materially more serious antimicrobial resistance signal than has previously been confirmed at EU/EEA level. This development is directly relevant to Bulgaria’s own sustained and substantial gonorrhoea case excess this year (discussed below), even though no resistance data are captured in routine Bulgarian surveillance.
Respiratory and Droplet Transmission
Respiratory Virus Season: Continued Inter-Seasonal Baseline
ECDC’s European Respiratory Virus Surveillance Summary confirms that influenza, RSV, and SARS-CoV-2 activity across the EU/EEA all remain at baseline, inter-seasonal levels as of Week 26 data, consistent with the expected mid-summer trough following the early and intense 2025–26 influenza season documented earlier in this report series. No changes have been made to ECDC’s SARS-CoV-2 variant of concern/interest/monitoring classifications since 29 May; VUM proportions for weeks 22–23 (based on very limited single-country sequencing data) show BA.3.2 at 72.7% and XFG at 27.3%, neither associated with any signal of increased severity or immune evasion. This section is included for surveillance continuity rather than as an active signal.
Infectious Diseases: Bulgaria
Fecal-Oral Transmission
Gastroenteritis and Enterocolitis
Acute gastroenteritis and enterocolitis registered 232 cases in Week 27, a 53-case (29.6%) increase from Week 26, comprising a syndromic surveillance mix of 78 possible, 146 probable, and only eight laboratory-confirmed cases. The year-to-date cumulative total of 4,212 cases remains essentially flat relative to the 4,230 cases recorded in the same period of 2025 (-0.4%), indicating that the Week 27 rise represents short-term volatility—plausibly linked to early-July temperature increases favouring foodborne and waterborne pathogen proliferation—rather than a sustained departure from the prior year’s seasonal trajectory. The high ratio of possible/probable to confirmed cases (96.6% non-confirmed) reflects the syndromic nature of this surveillance category in Bulgaria, which limits aetiological attribution without supplementary laboratory data.
Campylobacteriosis
Campylobacteriosis registered 15 cases in Week 27 (a one-case, 7.1% increase from Week 26, below the reporting threshold on its own), but the year-to-date cumulative total of 298 cases now stands 56.8% above the 190 cases recorded in the same period of 2025. This sustained year-over-year excess—consistent with the persistent signal documented throughout this report series in 2026—continues to represent one of the more durable enteric surveillance findings of the year, and its consistency across many consecutive weeks argues against a simple reporting artefact, though the specific driver (genuine incidence increase, improved case ascertainment, or a combination) cannot be determined from routine notification data alone.
Vector-Borne Transmission
Lyme Borreliosis
Lyme borreliosis registered 24 cases in Week 27, a nine-case (60.0%) increase from Week 26’s 15 cases, though the year-to-date cumulative total of 155 cases remains 5.5% below the 164 cases recorded in the same period of 2025. Borrelia burgdorferi sensu lato, transmitted by Ixodes ricinus, typically presents with erythema migrans, with untreated infection carrying risk of disseminated neurological, cardiac, or articular disease. The sharp single-week rise is consistent with peak-season tick activity in early July and should be interpreted within the context of a cumulative season that, unlike in prior years documented in this series, has not yet produced a year-to-date excess—continued monitoring through the remainder of the tick season will clarify whether 2026 ultimately tracks above or below 2025.
Mediterranean Spotted Fever
Mediterranean spotted fever (marsilska treska), caused by Rickettsia conorii and transmitted by the brown dog tick (Rhipicephalus sanguineus), registered seven cases in Week 27, a four-case (133.3%) increase from Week 26’s three cases (three probable, four confirmed). The year-to-date cumulative total of 35 cases remains 16.7% below the 42 cases recorded in the same period of 2025. As with Lyme borreliosis, the marked single-week increase is consistent with the seasonal peak of tick activity in early summer, and the modest absolute case numbers warrant continued but not escalated monitoring.
Bulgarian Coastal Municipalities and Vibrio Risk
As noted in the EU/EEA section above, ECDC’s Vibrio Viewer identifies 13 Bulgarian municipalities across the Varna, Dobrich, and Burgas regions as being at high environmental suitability for Vibrio spp. proliferation through 8 July, coinciding with the peak of the Black Sea bathing season; no Bulgarian vibriosis cases were reported in this week’s national surveillance bulletin, but the environmental forecast warrants continued clinical vigilance for compatible wound infections or gastroenteritis among individuals with recent coastal water or raw seafood exposure, particularly those with underlying hepatic disease, diabetes, or immunosuppression.
Measles: No District-Level Data Available This Week
No NCOZA/ZRZ district-level measles bulletin was available for the current reporting period, and NCIPD’s national operational analysis—consistent with the established routing of measles surveillance through the district-level system rather than national aggregate reporting—records no measles activity. This report series cannot therefore independently verify the current trajectory of Bulgaria’s ongoing measles outbreak this week; as of the most recent confirmed data (ECDC epidemic intelligence, 8 June), Bulgaria had recorded 364 cases year-to-date, concentrated in Vratsa, Pleven, and Lovech districts, and remained the second-highest national case contributor in the EU/EEA after England. Given the one-week reporting lag characteristic of ZRZ data relative to NCIPD aggregates, the next available district-level bulletin should be reviewed as a priority to confirm whether transmission has continued, plateaued, or declined since early June.
Contact and Sexual Transmission
Gonorrhea
Gonorrhea registered four cases in Week 27, a one-case (33.3%) increase from Week 26’s three cases, with the year-to-date cumulative total of 126 cases now 168.1% above the 47 cases recorded in the same period of 2025—the most pronounced year-over-year excess among tracked sexually transmitted infections in Bulgaria for 2026, consistent with the pattern documented throughout this report series. This trend gains additional significance in light of ECDC’s newly commenced EU/EEA-level risk assessment on ceftriaxone-resistant gonorrhoea and local transmission (discussed above); routine Bulgarian gonorrhoea surveillance does not capture antimicrobial susceptibility data, meaning that any resistant strains circulating domestically would not currently be detected through the national notification system.
Urogenital Chlamydial Infection
Urogenital chlamydial infection registered 12 cases in Week 27, a seven-case (140.0%) increase from Week 26’s five cases (one probable, 11 confirmed), with the year-to-date cumulative total of 189 cases representing a 133.3% excess over the 81 cases recorded in the same period of 2025. Chlamydia trachomatis—the most frequently reported bacterial sexually transmitted infection in the EU/EEA—is commonly asymptomatic, particularly in women, meaning routine surveillance data likely understate true incidence irrespective of the reporting trend; the sustained, substantial year-over-year excess documented across 2026 most plausibly reflects some combination of genuine transmission increase and improved case ascertainment, which cannot be disentangled using notification data alone.
Syphilis
Syphilis registered nine cases in Week 27, a seven-case (43.8%) decrease from Week 26’s 16 cases (one probable, eight confirmed)—a notable single-week decline that nonetheless leaves the year-to-date cumulative total of 216 cases 30.9% above the 165 cases recorded in the same period of 2025, continuing the sustained excess documented throughout this report series. The pronounced week-to-week volatility evident in syphilis notifications (a pattern also seen in preceding weeks of this series) is consistent with the relatively low absolute case counts involved and should not be over-interpreted as a change in underlying transmission dynamics on the basis of a single week’s data alone.